Madrigal PharmaceuticalsMIL:1MDGL 8 Buyback Yield % is 0.05 as of Jul. 08, 2026. GuruFocus rates MIL:1MDGL with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 740 Biotechnology companies, Madrigal Pharmaceuticals ranks better than 87.97% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1MDGL vs BMRN, AXSM, CYTK: Buyback Yield % Comparison
For the Biotechnology subindustry, Madrigal Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Madrigal Pharmaceuticals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Madrigal Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Madrigal Pharmaceuticals (MIL:1MDGL) has a Buyback Yield % of 0.05 as of Jul. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Madrigal Pharmaceuticals and its competitors. According to the industry distribution chart, Madrigal Pharmaceuticals ranks #89 out of 740 companies in the Biotechnology industry, placing it in the top 12%.
Is Madrigal Pharmaceuticals' Buyback Yield % too high?
Madrigal Pharmaceuticals' current Buyback Yield % is 0.05. Based on the distribution chart, Madrigal Pharmaceuticals ranks #89 out of 740 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Madrigal Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' Buyback Yield % compare to BMRN and AXSM?
According to the Biotechnology industry distribution chart, Madrigal Pharmaceuticals ranks #89 out of 740 companies for Buyback Yield %. This places Madrigal Pharmaceuticals in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Madrigal Pharmaceuticals and its competitors. Madrigal Pharmaceuticals's current Buyback Yield % is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MIL:1MDGL) has a current Buyback Yield % of 0.05. The current Buyback Yield % is 0.05. Madrigal Pharmaceuticals' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MIL:1MDGL), the current Buyback Yield % is 0.05 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
8GF Score
Get the complete analysis for MIL:1MDGL
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1MDGL has been successfully added to your 
